Altered Pathogenesis of Severe Pneumovirus Infection in Response to Combined Antiviral and Specific Immunomodulatory Agents
Open Access
- 15 January 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (2) , 1237-1244
- https://doi.org/10.1128/jvi.77.2.1237-1244.2003
Abstract
We report here the responses of mice with symptomatic pneumovirus infection to combined antiviral and specific immunomodulatory agents. Mice infected with pneumonia virus of mice, a natural mouse pathogen that replicates the signs and symptoms of severe infection with respiratory syncytial virus (RSV), responded to the antiviral agent ribavirin when it was administered in the setting of endogenous (gene deletion) or exogenous (antibody-mediated) blockade of the MIP-1α proinflammatory signaling cascade. Although neither treatment is effective alone, together they offer a dramatic reduction in symptoms and pathology, the most impressive of which is a significant reduction in morbidity and mortality. The findings presented are consistent with the notion of unique and independent contributions of virus replication and ongoing inflammation to the pathogenesis of severe respiratory virus infection, and they provide the impetus for the study of this treatment regimen in RSV-infected humans.Keywords
This publication has 37 references indexed in Scilit:
- Immune Interaction between Respiratory Syncytial Virus Infection and Allergen Sensitization Critically Depends on Timing of ChallengesThe Journal of Infectious Diseases, 2001
- Alternative Mechanisms of Respiratory Syncytial Virus Clearance in Perforin Knockout Mice Lead to Enhanced DiseaseJournal of Virology, 2001
- Macrophage Inflammatory Protein–1α (Not T Helper Type 2 Cytokines) Is Associated with Severe Forms of Respiratory Syncytial Virus BronchiolitisThe Journal of Infectious Diseases, 2001
- Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and GlucocorticosteroidThe Journal of Infectious Diseases, 2000
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Treatment of Parainfluenza Virus Type 3 Bronchiolitis and Pneumonia in a Cotton Rat Model Using Topical Antibody and GlucocorticosteroidThe Journal of Infectious Diseases, 1996
- Requirement of Mip-1α for an Inflammatory Response to Viral InfectionScience, 1995
- An Outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant CenterThe Journal of Infectious Diseases, 1992
- Aerosolized Ribavirin Treatment of Infants with Respiratory Syncytial Viral InfectionNew England Journal of Medicine, 1983